Table 3

Effectiveness of the trivalent influenza 2011–12 vaccine against influenza A(H3N2) in target group for vaccination by time since vaccination, in the early and late phase of the season, cycEVA study (weeks 52/2011 – 14/2012), Spain
Influenza activity phasea Time since vaccination Cases and controls (N/N) Vaccinated cases and controls (N/N) OR Influenza VE % (95% CI) Trend p valued
Early phase 45–75 days 110/63 1/8 Crude 94 (48;99) 0.119
Adjusted 95 (45;99)b
76–105 days 128/66 19/11 Crude 13 (−96;53)
Adjusted 48 (−31;80)c
106–135 days 131/64 22/9 Crude −23 (−186;47)
Adjusted 36 (−71;76)c
Late phase 39–81 days 29/16 0/1 Crude 0 0.518
Adjusted 0
82–123 days 47/21 18/6 Crude −55 (−372;49)
Adjusted −9 (−379;75)b
124–166 days 55/26 26/11 Crude −22 (−213;52)
Adjusted 15 (−214;77)b

aEarly phase: December 2011 – first half of February 2012; Late phase: Second half of February – April 2012. bModel adjusted for age groups (0–4, 5–14, 15–64 and >64 years), and week of swabbing. cModel adjusted for age groups (0–4, 5–14, 15–64 and >64 years), smoking habit, and week of swabbing. dTest for trend using time since vaccination as continuous.

Jiménez-Jorge et al.

Jiménez-Jorge et al. BMC Infectious Diseases 2013 13:441   doi:10.1186/1471-2334-13-441

Open Data